Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

nintedanib

ABPI London offices

ABPI toolkit to help pharma companies disclose trial data

Aims to improve transparency efforts in UK

- PMLiVE

UCB’s Steve Arnold joins ABPI board

Will work to support life sciences in the UK

Boehringer trials digital diabetes programme

Will study effect of self-management technology on clinical care

- PMLiVE

ADA: Boehringer/ Lilly’s empagliflozin shows blood glucose benefits

Phase III results for diabetes candidate also indicate significant weight loss

- PMLiVE

ABPI appoints new director of comms

Catherine Meaden was previously head of policy and public affairs at the body

- PMLiVE

ASCO: Boehringer’s nintedanib boosts survival in lung cancer subset

Trial date demonstrates benefit in NSCLC patients with adenocarcinomas

- PMLiVE

Boehringer/ Lilly launch online diabetes management game

Pharma companies aim to raise awareness of type 2 diabetes complications

Wireless pill bottle wins Boehringer healthcare innovation prize

AdhereTech's winning entry aims to increase patient adherence

- PMLiVE

England to launch 15 networks for NHS to work with academia

NHS England backs Academic Health Science Networks to spread innovation

ABPI London offices

ABPI: Pharma must sell outcomes, not products

Annual conference told industry must re-establish its social contract with the NHS

- PMLiVE

Boehringer backs gene therapy firm Eyevensys

Invests in French eye disease specialist

ABPI publishes updated guidance on pharmacovigilance and digital media

In a guest blog, the ABPI's Esteban Herrero-Martinez explains what changes to European pharmacovigilance legislation mean for ABPI members

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links